Latest Headlines

Latest Headlines

Two HeartMate II patients die while trying to switch to backup power source

Thoratec said that two patients died and one suffered a serious injury after they were unable to connect their HeartMate II left ventricular assist device to their backup system controller in a timely manner.

Potential bidders decline to challenge St. Jude's $3.4B bid for Thoratec

The 30-day "go-shop" period for LVAD maker Thoratec is over. No other bids to acquire the company were made. That means Thoratec is likely to become part of St. Jude Medical in the Q4, when the bigwig's $3.4 billion acquisition is expected to close.

FDA issues warning on heart pump safety issues: strokes, blood clots and bleeding

The FDA issued a public warning about the risks of left ventricular assist devices used to pump the blood of patients with end-stage heart failure, including strokes, the formation of blood clots inside the pump and bleeding complications.

Wall Street not anticipating another suitor for Thoratec on heels of St. Jude's $3.4B bid

The consensus is that none of the other medical device bigwigs will try and steal heart pump maker Thoratec from the clutches of St. Jude Medical during the $3.4 billion deal's 30-day "go-shop" period.

UPDATED: St. Jude to buy Thoratec for $3.4B, will pair its heart pump with the cardioMEMs patient monitor

St. Jude Medical announced its intention to acquire Thoratec, the maker of ventricular assist devices that pump the blood of patients awaiting a heart transplant, for $3.4 billion. Its stock price is up 2.5% on the news.

Bloomberg: St. Jude Medical discussing takeover of Thoratec

Industry bigwig St. Jude Medical is discussing a buyout of specialist Thoratec, a maker of left ventricular assist devices, which give heart failure patients awaiting a donated heart a bridge to organ transplantation by pumping their blood in the meantime. Thoratec stock is up 18% to around $58 on the rumor, as of 3 p.m.

Thoratec receives CE mark for new blood pump to assist patients during complex procedures

Thoratec received a CE mark for its HeartMate Percutaneous Heart Pump, following a 30-person clinical trial.

Clinical trial finds Thoratec heart failure device better than medical management

Thoratec touted clinical trial data presented at an International Society for Heart and Lung Transplantation meeting in Nice, France, showing that advanced heart failure patients who receive ambulatory--or outpatient--care are better off using its HeartMate II left ventricular assist device than receiving optimal medical management.

Physicians hesitate to use HeartMate II pump after NEJM study, Thoratec down 30%

Thoratec shed almost one-third of its value after reporting abysmal second quarter earnings. The advanced heart failure device company attributed most of the miss to a New England Journal of Medicine article that came out late last year and linked the company's HeartMate II left ventricular assist device to an increasing rate of pump thrombosis.

Thoratec boosts sales, but profits stay flat

Thanks to its banner HeartMate device, Thoratec handed in another quarter of solid revenue growth, but a spike in costs kept its net income from moving upward.